Unique associated Kaposi's Sarcoma virus sequences and uses thereof
AssigneeThe Trustees of Columbia University in the City of New York
InventorsYuan Chang, Roy A. Bohenzky, James J. Russo, Isidore S. Edelman, Patrick S. Moore
Life of this patent
Estimating the term…
Abstract
This invention provides an isolated nucleic acid molecule which encodes Kaposi's Sarcoma-Associated Herpesvirus (KSHV) polypeptides. This invention provides an isolated polypeptide molecule of KSHV. This invention provides an antibody specific to the polypeptide. Antisense and triplex oligonucleotide molecules are also provided. This invention provides a vaccine for Kaposi's Sarcoma (KS). This invention provides methods of vaccination, prophylaxis, diagnosis and treatment of a subject with KS and of detecting expression of a DNA virus associated with Kaposi's sarcoma in a cell.
Claims15
An isolated nucleic acid which corresponds to an open reading frame within Kaposi's sarcoma-associated herpesvirus selected from the group of nucleic acids having the following sequences:
- a) in SEQ ID NO:
- 17:
- 1) nucleotide number 11,363 to nucleotide number 14,401 (ORF9);
- 2) nucleotide number 21,104 to nucleotide number 20,091 (ORF70)
- 3) nucleotide number 22,529 to nucleotide number 22,185 (vMIP III);
- 4) nucleotide number 27,424 to nucleotide number 27,137 (ORF K6);
- b) in SEQ ID NO:
- 18:
- 1) nucleotide number 283 to nucleotide number 2,025 (ORF21);
- 2) nucleotide number 20,876 to nucleotide number 22,210 (ORF36);
- c) in SEQ ID NO:
- 19:
- 1) nucleotide number 2,534 to nucleotide number 4,429 (ORF50);
- 2) nucleotide number 4,650 to nucleotide number 5,369 (ORF K8);
- d) in SEQ ID NO:
- 20:
- 1) nucleotide number 12,801 to nucleotide number 12,619 (ORF K12);
- and
- 2) nucleotide number 30,979 to nucleotide number 30,677 (ORF K15).
Dependencies are inferred from the claim text.